Company* (Country; Symbol) | Funding Institution | Amount (M) |
Type | Details (Date) |
| ||||
Aastrom Biosciences Inc. (ASTM) |
National Cancer Institute |
$0.124 |
Phase I SBIR grant |
For eight-month study to demonstrate feasibility of using its cell-production technology to develop an immunotherapeutic for malignant melanoma (4/22) |
Adenosine Therapeutics LLC* |
National Institutes of Health |
$1.38 |
Phase II SBIR grant |
To fund research on an oral blocker of adenosine receptors for treating Type II diabetes (4/22) |
Agennix Inc.* |
National Institute of Allergy and Infectious Diseases |
ND |
Phase I SBIR grant |
To fund further characterization of the efficacy of oral recombinant human lactoferrin in a primate model of asthma (5/25) |
Albany Molecular Research Inc. (AMRI) |
National Institute on Drug Abuse |
$3 |
Contract award |
Three-year deal worth up to $3M to provide chemical manufacturing of drug substances for use in products for treating substance abuse (5/7) |
Althea Technologies Inc.* |
National Institute on Deafness and Other Communication Disorders |
ND |
Phase I SBIR grant |
To develop and validate gene sets and predictive classifiers for specific toxicological endpoints (6/23) |
Athersys Inc.* |
Juvenile Diabetes Research Foundation |
ND |
Grant |
To fund research focused on identifying proteins that pro- mote the formation of pancreatic islet cells; Athersys will apply its technologies to the effort (6/4) |
Australian companies |
AusBiotech (Australia; industry organization) |
A$87.1 (US$60.7) |
Pharmaceutical Partnerships Program awards |
Receiving awards were Acrux Ltd. (A$4.2M), AGC Biosciences Ltd. (A$8.4M), Amrad Corp. Ltd. (A$5.2M), CSL Ltd. (A$10M), Mayne Pharmaceuticals (A$10M), Novogen Ltd. (A$10M) and Pharmaxis Ltd. (A$6.1M) (4/22) |
Avant Immunotherapeutics Inc. (AVAN) |
Department of Defense |
$3 |
Subcontract award with DynPort Vaccine Co. LLC |
To support human clinical testing of a plague vaccine candidate from Avant for use in a combiination anthrax/plague oral vaccine (4/21) |
Basilea Pharmaceutica AG (Switzerland; SWX:BSLN) |
European Commission |
€1.56 (US$1.9) |
EU research grant |
Basilea and academic partners in Combigyrase consortium will develop antibiotics targeting gyrase through combinatorial biosynthesis (6/30) |
BioVeris Corp. (BIOV) |
Department of Defense |
$7 |
Purchase agreements |
The DoD exercised its option to purchase up to $7M of BioVeris products for detecting specific biological agents (6/24) |
Cepheid Inc. (CPHD) |
National Cancer Institute |
$1.88 |
Grant |
Two-year award will fund validation of the GeneXpert platform for the isolation and detection of tumor markers in tissue sections (5/24) |
Ceptor Inc. (subsidiary of Xechem International Inc.; OTC BB: XKEM) |
National Institutes of Health |
$0.145 |
Grant |
To support a project to study calpain inhibitors in protecting hearing loss (5/19) |
Chiron Corp. (CHIR) |
National Institute of Allergy and Infectious Diseases |
ND |
Contract award |
To produce an investigational vaccine against the H5N1 strain of avian influenza, which struck China and the Far East (5/27) |
Commonwealth Biotechnologies Inc. (CBTE) |
Undisclosed U.S. government agencies |
$1.7 |
Contract awards |
The projects include production of pathogens, immunogenicity assessment of select agent vaccines and analyses of clinical trials (5/11) |
ECI Biotech Inc.* |
National Eye Institute |
ND |
Grant |
For in vitro analysis of inhibition of proteolytic enzymes for treating microbial keratitis (6/11) |
Enkam Pharmaceuticals A/S (Denmark); Reglia AB* (Sweden); Schaefer-N A/S* (Denmark); and Neuropharma SA (unit of Zeltia Group; Spain) |
European Union |
€9.7 (US$11.7) |
Grant |
Companies are among the 18 groups from 11 EU countries that will share the funds from the Promemoria project; the work focuses on the NCAM molecule for Alzheimer's disease (6/17) |
Epigenomics AG* (Germany) |
German Ministry for Education and Research |
€1.1 (US$1.3) |
BMBF grant |
The grant will support a three- year project including academic collaborators to develop tech- niques for high-throughput early cancer screening based on DNA methylation (4/27) |
Epimmune Inc. (EPMN) |
National Cancer Institute |
$0.8 |
Grant |
Two-year grant to support the continued analysis of immune responses to its multi-epitope cancer vaccine, EP-2101 (5/11) |
FASgen Inc. * |
National Cancer Institute |
$2.4 |
Grant |
To support Phase II studies of of FASgen's fatty-acid synthase inhibitors in ovarian cancer (4/7) |
First Genetic Trust Inc.* |
National Institute of Standards and Technology |
$2 |
Advanced Technology Program grant |
To support development of a secure information system that manages patients' medical and genetic data for use in surveillance of adverse reactions and pharmacogenomic research (5/11) |
454 Life Sciences (subsidiary of CuraGen Corp.; CRGN) |
National Human Genome Research Institute |
$2.4 |
Grant |
Two-year grant will help fund the scale-up of technology for sequencing of larger genomes (5/19) |
Gamida-Cell Ltd.* (Israel) |
The Office of the Chief Scientist (Israel) |
$1.3 |
Grant |
To support stem cell research involving Gamida's StemEx product in cancer and cardiac indications (5/17) |
Gene Logic Inc. (GLGC) |
National Cancer Institute |
$6.9 |
Contract |
Multiyear deal under which Gene Logic will provide preclinical safety and pharmacology studies for the NCI; it could earn $6.9M over seven years (4/8) |
Gene Network Sciences* |
Department of Energy |
$2.5 |
Grant under Genomics: GTL program |
Three-year grant to create a computational hypothesis-testing framework to infer probable net- work architectures in cells in a massively parallel computing environment (5/11) |
GenOway SA* (France) |
The French Agency for Innovation and the Ministry of Research (France) |
€1 (US$1.2) |
Research support |
The funding will support the company's EUREKA-labeled program for developing genetically modified rats (5/20) |
Incara Pharmaceuticals Corp. (OTC BB:ICRA) |
National Cancer Institute |
$0.375 |
Phase II SBIR grant |
To study the antitumor and radiation-protective effects of Incara's catalytic antioxidants (4/1) |
Incell Corp.* |
U.S. Air Force |
ND |
Contract award |
To further develop an oral smallpox vaccine and platform based on the use of modified vaccinia Ankara (5/5) |
Inotek Pharmaceuticals Corp.* |
National Institutes of Health |
ND |
Phase I SBIR grant |
To support preclinical studies of the company's lead product for treating organophosphate toxicity-related brain damage (4/30) |
Intradigm Corp.* |
National Eye Institute |
ND |
Phase I SBIR grant |
To support development of the company's lead anti-angiogenesis siRNA therapeutic for eye neo- vascularization diseases (6/21) |
Intradigm Corp.* |
National Cancer Institute |
ND |
Phase I STTR grant |
To support work with the University of Maryland on nucleic acid delivery technology targeting brain tumors and their blood vessels (6/9) |
Intradigm Corp.* |
National Cancer Institute |
ND |
Phase I SBIR grant |
To support development of the company's lead cancer siRNA therapeutic, which is designed to inhibit the VEGF pathway (5/20) |
Introgen Therapeutics Inc. (INGN) |
National Cancer Institute |
$1.2 |
STTR grant |
To support a recently initiated Phase II trial of INGN 241 in malignant melanoma (4/13) |
Juvaris BioTherapeutics Inc.* |
National Institute of Allergy and Infectious Diseases |
ND |
Phase I SBIR grant |
The grant will fund initial studies of a vaccine against Pseudmonas aeruginosa, which uses cationic lipid-DNA complexes (5/18) |
Kosan Biosciences Inc. (KOSN) |
National Cancer Institute |
$0.75 |
Phase II SBIR grant |
Two-year grant to support development of next-generation inhibitors of heat-shock protein 90 as potential cancer agents (4/13) |
Kosan Biosciences Inc. (KOSN) |
National Cancer Institute |
$0.75 |
Phase II SBIR grant |
To develop an efficient means of producing analogues of the polyketide discodermolide, an agent being studied for cancer (4/1) |
LigoCyte Pharmaceuticals Inc.* |
Department of Defense |
$2.18 |
Contract award |
To support continued development of drugs for norovirus infections, which cause gastroenteritis (6/25) |
Mologen AG* (Germany) |
Ministry of Education and Research (Germany) |
€0.26 (US$0.31) |
BioChancePLUS program grant |
To support DNAShield program of developing a two-component vaccine against aggressive infections; support for the two-year program could total €0.86M (4/7) |
MycoLogics Inc.* |
Department of Health and Human Services |
ND |
Phase I SBIR grant |
To isolate a new class of com- pounds by disrupting beta(1,3)- glucan synthesis using a novel assay (4/3) |
NewNeural LLC* |
National Institute on Aging |
ND |
Phase I SBIR grant |
To support development of the small molecule NN-818TM, which is being developed to increase neural stem cells (5/24) |
NovaRx Corp.* |
National Institutes of Health |
$2 |
SBIR grant |
The grant, payable over four years, will help fund a pivotal Phase II/III trial of the company's therapeutic vaccine for brain cancer (5/12) |
Novozymes A/S (Denmark; CSE: NZYM) |
National Renewable Energy Laboratory |
$2.3 |
Subcontract award |
They extended three-year deal for one year; the work involves converting cellulosic biomass into sugars for fuel ethanol and other products (4/26) |
One Cell Systems Inc.* |
National Cancer Institute |
$0.95 |
Phase II SBIR grant |
To develop fluorescence in situ hybridization assays for detecting mRNA telomerase in cancer cells (4/21) |
Oridis Biomed* (Austria); PSF Biotech* (Germany); Nascacell IP* (Germany); and Tripos Receptor Research* (UK) |
European Union |
€2.5 (US$3.1) |
Sixth Research Framework Program grants genomics targets (5/11) |
The four companies along with two academic partners will work on parallel optimization in the development of new oncology |
Oxford BioMedica plc (UK; LSE:OXB) |
Christopher Reeve Foundation |
$0.15 |
Grant |
To support the company's Innurex program for nerve regeneration in spinal cord injury (4/20) |
Oxford BioMedica plc (UK; LSE:OXB) |
Department of Health (UK) |
£0.5 (US$0.89) |
Grant |
To develop its LentiVector technology for use in treating single-gene inherited disorders, focusing on hemophilia A (3/29)** |
Panacea Pharmaceuticals Inc.* |
National Institute of Aging |
ND |
Phase I SBIR grant |
To evaluate PAN-811 and its derivatives as neuroprotectants for global and focal ischemia (4/6) |
Paradigm Genetics Inc. (PDGM) |
National Institute of Environmental Health Sciences |
ND |
Contract expansion |
For additional work using small interfering RNA technology in toxicogenomics research, which Paradigm is doing under a five- year deal begun in 2002 (5/6); expanded deal to include a study of four to six additional known liver toxicants (6/28) |
Paradigm Genetics Inc. (PDGM) |
National Institutes of Health |
$0.85 |
Phase I/II SBIR contract |
To apply biochemical profiling to the discovery of biomarkers for alcohol-related diseases (6/23) |
Paradigm Genetics Inc. (PDGM) |
National Institute of Environmental Health Sciences |
ND |
Phase I/II SBIR contract |
Fast-track contract will support efforts to discover biochemicals in urine, serum and liver tissue that predict the early onset of drug-induced liver injury (6/21) |
Perlegen Sciences Inc.* and the Mayo Clinic |
The Michael J. Fox Foundation for Parkinson's Research |
$2.8 |
Grant |
Up to $2.8M could be earned for whole-genome association studies of Parkinson's disease, using Perlegen's genotyping technology and Mayo's DNA samples (6/14) |
Pharmos Corp. (PARS) |
Israel's Ministry of Industry and Trade |
$3.1 | Office of the Chief Scientist grant |
The grant is for up to $3.1M to support development of dexanabinol in traumatic brain injury (4/1) |
Phase 2 Discovery Inc.* |
National Institute of Mental Health |
$1.25 |
Phase II SBIR grant |
To support Phase II trials of the synthetic melatonin analogue PD- 735 in primary insomnia (5/12) |
Phylogeny Inc.* |
State of Ohio |
$1.1 |
Grant |
To launch manufacturing of its next generation of tissue arrays (5/5) |
Phylonix Pharmaceuticals Inc.* |
National Cancer Institute |
$0.993 |
Phase II SBIR grant assays for drug screening (6/2) |
The $993,463 grant will be used to develop zebrafish apoptosis |
Pieris Proteolab AG* (Germany) |
Ministry of Education and Research (Germany) |
€2 (US$2.4) |
BioChance PLUS program grant |
To validate Anticalins in pre- clinical development and to develop manufacturing processes against targets in oncology and cardiovascular diseases (5/7) |
Piramed Ltd.* (UK) and The Institute of Cancer Research (UK) |
Accelerate Brain Cancer Cure |
ND |
Grant |
For preclinical evaluation of candidates resulting from their collaboration on targeting the PI3 kinase pathway to discover cancer drugs (5/20) |
Protiveris Inc.* |
Maryland Industrial Partnerships program |
$0.116 |
Award |
For optimization of a microfluidic sample delivery system in the company's biosensor system (4/1) |
Provectus Pharmaceuticals Inc. (OTC BB:PVCT) |
The Prostate Cancer Foundation |
$0.120 |
Research award |
The two-year award to the University of Wisconsin at Madison is to study Provectus' PV-10 cancer drug (4/1) |
Resverlogix Corp. (Canada; TSE:RVX) |
National Research Council of Canada |
C$0.18 (US$0.133) |
Industrial Research Assistance Program agreement |
To fund further development of the APO A1 assay screening process, which is used to identify lead compounds (6/21) |
Ribonomics Inc.* |
National Institutes of Health |
$0.663 |
Two SBIR grants |
One grant is to apply its RAS technology to understanding signaling processes in beta-cell function; the second is aimed at identifying signaling pathways involved in leptin receptor-regulated physiology (4/26) |
Sangamo BioSciences Inc. (SGMO) |
National Institute of Standards and Technology |
$2 |
Advanced Technology Program grant |
Three-year grant will support research on an application of its zinc finger DNA-binding protein transcription factor technology (5/4) |
Sinovac Biotech Ltd. (China; OTC BB: SNVBF) |
National Institutes of Health |
ND |
Development support |
Sinovac received funding sup- port for a SARS vaccine research project that will test responses in bioassays (5/19) |
SRI Internaitonal* |
National Cancer Institute |
$12.3 |
Contract awards |
SRI will evaluate the preclinical safety and pharmacology of potential therapeutic agents under seven-year contracts (6/26) |
SRI International* |
National Institute of General Medical Sciences |
ND |
Grant |
To expand development of the MetaCyc metabolic pathway and enzyme technology, which was developed in collaboration with the Carnegie Institution (5/17) |
Syrrx Inc.* |
National Institute of Standards and Technology |
ND |
Advanced Technology Program grant |
To facilitate the development of nanoscale arrays and processes that improve the crystallization of medically important proteins (5/3) |
The Immune Response Corp. (IMNR) |
The Immune Tolerance Network |
ND |
Grant |
The grant was awarded to Oregon Health Sciences University to support research on NeuroVax, an agent being developed for multiple sclerosis (4/6) |
Thuris Corp.* |
National Institutes of Health |
ND |
STTR grant |
For development of drugs for certain orphan indications in central nervous system diseases (6/24) |
TransTech Pharma Inc.* |
Department of Defense |
$0.065 |
Phase I SBIR grant |
To enhance its computational technology to generate molec- ular models and use them to design chemical inhibitors for targets of interest to the U.S. Army (5/11) |
TransTech Pharma Inc.* |
National Institute of Allergy and Infectious Diseases |
$0.665 |
Phase I SBIR grant |
To identify and optimize potential small-molecule drugs to treat smallpox (5/11) |
U.S. Genomics Inc.* |
U.S. Department of Homeland Security |
$7.5 |
Contract |
Eighteen-month contract to develop a biological sensor to detect and identify airborne pathogens using its GeneEngine DNA-mapping technology (5/10) |
Viragen Inc. (AMEX:VRA) |
Scottish government |
$0.833 |
Grant under SPUR Plus program |
To support research and development of Viragen's anti-CD55 cancer antibody (4/15) |
ViRexx Medical Corp. (Canada; TSE:VIR) |
Alberta Heritage Foundation for Medical Research (Canada) |
$0.5 |
Phase 3 Technology Commercialization Award |
To help fund a Phase I trial of Occlusion Injection in liver cancer, which is expected to start in 2H:04 (4/26) |
ViroLogic Inc. (VLGC) |
National Institutes of Health |
ND |
Phase II SBIR grant |
The follow-on grant will be used to assess HIV replication capacity as a predictor of the pace of progression to clinical AIDS (6/24) |
Xenon Genetics Inc.* (Canada) |
Genome Canada and Genome British Columbia |
C$7 (US$5.2) |
Research funding |
Xenon will provide matching funds for the three-year project to develop improved diagnostics and therapeutics for common iron metabolism disorders (4/13) |
Notes: | ||||
* Indicates a privately held company. | ||||
** Item happened before April 1 but was not included in the previous chart. | ||||
Currency conversions reflect values at the time of a deal's announcement. | ||||
SBIR = Small Business Innovation Research; STTR = Small Business Technology Transfer. | ||||
Unless otherwise indicated, symbols listed are on the Nasdaq market. | ||||
AMEX = American Stock Exchange; CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SWX = Swiss Stock Exchange; TSE = Toronto Stock Exchange. |